AMGN vs INSM vs REGN Stock Comparison

Amgen, Insmed and Regeneron Pharmaceuticals Prices as of Nov 13, 2026 Peers: Industry group
AMGN Amgen Inc
$465.67 +9.3% 1M +38.6% 1Y
Market cap
$253.47B
P/E
27.0x
Revenue (TTM)
$38.90B
Div. yield
0.02%
Biotechnology Healthcare
4 wins
INSM INSMED Inc
$121.16 +23.9% 1M -36.6% 1Y
Market cap
$27.11B
P/E
–
Revenue (TTM)
$1.52B
Div. yield
–
Biotechnology Healthcare
2 wins

Head to Head

11 decided of 12

Regeneron Pharmaceuticals leads on 5 of the 12 questions below (Regeneron Pharmaceuticals 5, Amgen 4, Insmed 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionAMGNINSMREGNLeader
Larger companyMarket capitalisation $253.47B $27.11B $97.62B AMGN
Cheaper on earningsLower P/E, profitable companies only 27.0x -44.8x 20.3x REGN
Cheaper on forward earningsLower price / next fiscal year consensus EPS 20.9x — 14.8x REGN
Faster revenue growthRevenue growth, trailing twelve months +8.2% +240.0% +18.6% INSM
More profitableNet margin, trailing twelve months 24.1% -39.9% 28.5% REGN
Better return on capitalReturn on invested capital 15.6% -41.1% 11.9% AMGN
Less leveragedLower net debt / EBITDA 2.4x 1.1x -1.4x REGN
Higher dividend yieldTrailing dividend yield 0.02% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +38.6% -36.6% +37.5% AMGN
Better 5-year returnAnnualised price return, 5 years +17.1%/yr +30.6%/yr +8.7%/yr INSM
Less volatileAnnualised volatility, 1 year 28.8% 62.2% 33.9% AMGN
Higher overall scoreMean of the five percentile scores vs peers 66/100 66/100 73/100 REGN

Percentile Scorecard

AMGNINSMREGN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisAMGNINSMREGN
Valuation 85 #103 of 660 70 #201 of 660 89 #75 of 660
Growth 61 #245 of 619 85 #91 of 619 50 #308 of 619
Profitability 95 #32 of 595 69 #186 of 595 92 #48 of 595
Financial Health 23 #528 of 683 37 #428 of 683 71 #199 of 683
Shareholder Returns 67 #152 of 459 67 #153 of 459 63 #170 of 459
Overall 66 66 73
  • AMGN ranked among 695 companies in Pharmaceuticals and Biotechnology
  • INSM ranked among 695 companies in Pharmaceuticals and Biotechnology
  • REGN ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodAMGNINSMREGNSPY
1 month +9.3%+23.9%+22.8% -2.0%
3 months +12.2%-2.1%+18.9% -2.8%
6 months +42.7%+11.0%+36.8% +2.0%
Year to date +42.3%-30.4%+23.8% +10.6%
1 year +38.6%-36.6%+37.5% +12.2%
3 years +72.5%+393.7%+20.4% +68.1%
3 years, per year +19.9%+70.3%+6.4% +18.9%
5 years +120.3%+280.3%+51.4% +61.4%
5 years, per year +17.1%+30.6%+8.7% +10.1%
10 years +212.4%+738.5%+127.6% +248.5%
10 years, per year +12.1%+23.7%+8.6% +13.3%

Risk

MeasureAMGNINSMREGNSPY
Volatility, 1Y 28.8%62.2%33.9% 13.6%
Downside volatility, 1Y 28.4%61.0%30.8% 13.9%
Beta vs S&P 500, 1Y 0.490.550.35 1.00
Return / volatility, 1Y 1.34-0.591.11 0.90
Max drawdown, 5Y -26.7%-56.5%-59.8% -25.4%
From 52-week high -2.7%-42.7%-1.8% -3.2%
52-week high $478.48$211.41$973.36 $779.14
52-week low $313.85$91.88$600.66 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleAMGNINSMREGN
P/E now vs peer median 26.8xmedian 17.0x -43.8xmedian 17.0x 20.2xmedian 17.0x
P/S now vs peer median 6.5xmedian 8.4x 17.5xmedian 8.4x 5.8xmedian 8.4x
EV/EBITDA now vs peer median 17.1xmedian 14.6x -48.6xmedian 14.6x 16.7xmedian 14.6x
P/FCF now vs peer median 26.3xmedian 19.0x -42.3xmedian 19.0x 25.4xmedian 19.0x
P/B now vs peer median 17.6xmedian 2.0x 36.6xmedian 2.0x 2.9xmedian 2.0x
PEG now vs peer median 3.86median 0.43 -2.40median 0.43 2.23median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsAMGNINSMREGN
Revenue $38.90B $1.52B $16.90B
Gross profit $27.58B $1.28B $14.49B
Operating income $12.61B -$563.99M $4.86B
Net income $9.39B -$605.67M $4.82B
Free cash flow $9.58B -$627.58M $3.83B
R&D $7.84B $944.39M $6.60B
EPS (diluted) $17.20 $-2.77 $45.62
Cash & equivalents $13.19B $396.60M $3.66B
Total debt $54.01B $555.09M $1.99B
Shares (diluted) 546.00M 218.79M 105.60M
Enterprise value $205.13B $22.15B $62.97B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricAMGNINSMREGN
P/E 26.8x -43.8x 20.2x
P/FCF 26.3x -42.3x 25.4x
P/Operating cash flow 20.9x -44.6x 20.1x
P/S 6.5x 17.5x 5.8x
P/B 17.6x 36.6x 2.9x
P/Tangible book -48.6x 45.2x 3.0x
EV/EBITDA 17.1x -48.6x 16.7x
EV/EBIT 23.2x -46.1x 18.5x
EV/Revenue 7.5x 17.1x 5.3x
EV/FCF 30.5x -41.4x 23.5x
EV/Operating cash flow 24.3x -43.6x 18.5x
PEG (3Y EPS CAGR) 3.86 -2.40 2.23

Growth

14 metrics
MetricAMGNINSMREGN
Revenue growth (1Y) 8.2% 240.0% 18.6%
Revenue CAGR (3Y) 13.2% 75.6% 8.9%
Gross profit growth (1Y) 15.9% 274.9% 19.1%
Gross profit CAGR (3Y) 11.8% 79.8% 8.8%
Operating income growth (1Y) 45.4% 51.3% 31.9%
Operating income CAGR (3Y) 12.5% 6.2% 4.8%
Net income growth (1Y) 34.1% 48.8% 5.2%
Net income CAGR (3Y) 7.5% 5.8% 6.5%
EPS growth (1Y) 33.1% 50.5% 6.8%
EPS CAGR (3Y) 6.9% 18.2% 9.0%
Operating cash flow growth (1Y) -8.3% 32.6% -4.4%
Operating cash flow CAGR (3Y) 4.4% -5.4% -2.5%
Free cash flow growth (1Y) -17.0% 30.7% -9.4%
Free cash flow CAGR (3Y) 0.7% -6.2% -6.0%

Profitability

14 metrics
MetricAMGNINSMREGN
Gross margin 70.9% 84.4% 85.8%
EBITDA margin 43.9% -35.1% 31.8%
Operating margin 32.4% -37.1% 28.8%
Pretax margin 28.4% -39.4% 33.7%
Net margin 24.1% -39.9% 28.5%
FCF margin 24.6% -41.3% 22.6%
Operating cash flow margin 30.9% -39.2% 28.7%
Return on equity 72.1% -81.9% 14.0%
Return on assets 9.8% -28.1% 10.6%
Return on invested capital 15.6% -41.1% 11.9%
Return on capital employed 17.4% -36.0% 13.2%
Asset turnover 0.4x 0.7x 0.4x
Cash conversion (OCF / net income) 1.3x 1.0x 1.0x
Stock comp / revenue 1.3% 11.0% 6.0%

Financial Health

11 metrics
MetricAMGNINSMREGN
Debt / assets 56.2% 24.9% 4.5%
Debt / equity 3.8x 0.8x 0.1x
Net debt / EBITDA 2.4x 1.1x -1.4x
Debt / FCF 5.6x -0.9x 0.5x
Liabilities / assets 85.1% 67.4% 24.6%
Equity / assets 14.9% 32.6% 75.4%
Interest coverage 4.8x -5.5x 104.2x
Current ratio 1.5x 2.9x 3.4x
Quick ratio 1.0x 2.4x 2.7x
Cash ratio 0.6x 1.9x 1.5x
Altman Z-score 2.54 7.36 7.73

Shareholder Returns

7 metrics
MetricAMGNINSMREGN
Dividend yield 2.1% – 0.4%
Net buyback yield – -0.4% 2.1%
Shareholder yield 2.1% -0.4% 2.5%
Payout ratio (earnings) 57.1% – –
Payout ratio (FCF) 56.0% – –
Dividend growth (1Y) 6.3% – –
Dividend CAGR (3Y) 6.4% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusAMGNINSMREGN
Forward P/E 20.9xFY2026 – 14.8xFY2026
EPS, next fiscal year $22.28FY2026 $-1.68FY2026 $64.62FY2026
EPS growth, next FY +2.0%FY2026 – +45.8%FY2026
EPS growth, the year after +7.2% – +13.6%
Revenue, next fiscal year $42.01BFY2026 $1.99BFY2026 $18.08BFY2026
Revenue growth, next FY +14.3%FY2026 +227.7%FY2026 +26.1%FY2026
Revenue growth, the year after +3.1% +59.5% +14.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersAMGNINSMREGN
Held by institutions 82.7% 100.0% 66.2%
Institutions holding 3,163 671 1,329
Change in shares held, QoQ +4.5% +3.4% +3.8%
Institutions buying 1,452 369 607
Institutions selling 1,219 230 534
Buyers to sellers 1.19 1.60 1.14

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

AMGNINSMREGN
AMGN 1.00 0.15 0.46
INSM 0.15 1.00 0.16
REGN 0.46 0.16 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, AMGN, INSM and REGN?

Amgen (AMGN) is the largest by market capitalisation: Amgen (AMGN) $253.47B, Insmed (INSM) $27.11B, Regeneron Pharmaceuticals (REGN) $97.62B.

Which stock is cheaper, AMGN, INSM and REGN?

Regeneron Pharmaceuticals (REGN) trades on the lowest price-to-earnings ratio (Amgen (AMGN) 27.0x, Insmed (INSM) -44.8x, Regeneron Pharmaceuticals (REGN) 20.3x). On next year's consensus earnings, Regeneron Pharmaceuticals (REGN) is cheapest (Amgen (AMGN) 20.9x, Regeneron Pharmaceuticals (REGN) 14.8x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Insmed (INSM) grew revenue fastest over the trailing twelve months: Amgen (AMGN) +8.2%, Insmed (INSM) +240.0%, Regeneron Pharmaceuticals (REGN) +18.6%.

Which company is more profitable?

Regeneron Pharmaceuticals (REGN) has the highest net margin (Amgen (AMGN) 24.1%, Insmed (INSM) -39.9%, Regeneron Pharmaceuticals (REGN) 28.5%). On return on invested capital, Amgen (AMGN) leads (Amgen (AMGN) 15.6%, Insmed (INSM) -41.1%, Regeneron Pharmaceuticals (REGN) 11.9%).

Which stock has performed better?

Over the past year Amgen (AMGN) returned the most: Amgen (AMGN) +38.6%, Insmed (INSM) -36.6%, Regeneron Pharmaceuticals (REGN) +37.5%. Over five years, Insmed (INSM) compounded fastest (Amgen (AMGN) +17.1%/yr, Insmed (INSM) +30.6%/yr, Regeneron Pharmaceuticals (REGN) +8.7%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Amgen (AMGN) 0.02%, Insmed (INSM) 0.00%, Regeneron Pharmaceuticals (REGN) 0.00%. Insmed (INSM) and Regeneron Pharmaceuticals (REGN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Amgen (AMGN) has been the steadiest (Amgen (AMGN) 28.8%, Insmed (INSM) 62.2%, Regeneron Pharmaceuticals (REGN) 33.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, AMGN, INSM and REGN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Regeneron Pharmaceuticals (REGN) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.